Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

An alternative approach for treatment of breast cancer

Summary

Since adjuvant chemotherapy and hormonal therapy generally extend disease free survival in breast cancer rather than provide a cure, we have examined the current breast cancer paradigm. Heterogeneity is a fundamental characteristic of breast cancer tissue and a well recognized aspect of the disease. There are variations in natural history, histopathology, biochemistry and endocrinology, and molecular biology of cancer tissues and cells within the tissues. A variety of data indicate that growth kinetics are also variable, not only from tumor to tumor, but also during the natural history of an individual's tumor. To better understand kinetic heterogeneity, a stochastic numeric computer model of the natural history of breast cancer has been developed. To be consistent with inter- and intratumor kinetic heterogeneity and with late relapse, the model predicts that tumors grow in an irregular fashion with alternating periods of growth and periods of dormancy rather than the generally accepted modified exponential, or Gompertzian fashion. The prediction of irregular growth has been compared to data relevant to growth characteristics of human breast cancer. Much data support the concept of irregular kinetics and temporary dormancy rather than steady, Gompertzian growth of human breast cancer. Thus, in addition to drug resistance, kinetic heterogeneity may help explain the limited impact that traditional chemotherapeutic treatment has had on mortality from breast cancer. Although the mechanisms underlying irregular growth need to be better understood, non-Gompertzian growth kinetics indicates that there may be alternative approaches for breast cancer treatment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Miller BA, Feuer EJ, Hankey BF: Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 43: 27–41, 1993

  2. 2.

    Bonadonna G: Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380–1397, 1989

  3. 3.

    Thomlinson RH: Measurement and management of carcinoma of the breast. Clin Radiol 33: 481–493, 1982

  4. 4.

    Prehn RT: The inhibition of tumor growth by tumor mass. Cancer Res 51: 2–4, 1991

  5. 5.

    Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067–7071, 1988

  6. 6.

    DeVita VT Jr: The relationship between tumor mass and resistance to chemotherapy. Cancer 51: 1209–1220, 1983

  7. 7.

    Laird AD: Dynamics of growth in tumors and in normal organisms. NCI Monograph 30: 15–28, 1969

  8. 8.

    Meltzer A: Dormancy and breast cancer. J Surg Oncol 43: 181–188, 1990

  9. 9.

    Hadfield G: The dormant cancer cell. Br Med J 2: 607–610, 1954

  10. 10.

    Willis RA: The Spread of Tumors in the Human Body. Butterworths and Co, Ltd, London, (ed 3) 1952

  11. 11.

    Gilbert SF: Developmental Biology. Sinauer, Sunderland, MA, (ed 3) 1991

  12. 12.

    Pierce GB: Teratocarcinoma: model for a developmental concept of cancer. Curr Top Dev Biol 2: 223–246, 1967

  13. 13.

    Pierce GB, Speers WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48: 1996–2004, 1988

  14. 14.

    Ponten J,et al.: Biology and natural history of breast cancer. Int J Cancer Suppl 5: 5–21, 1990

  15. 15.

    Musgrove EA, Lee CSL, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 11: 5032–5043, 1991

  16. 16.

    Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1–8, 1991

  17. 17.

    Cole MP, Jones CJA, Todd IDH: A new antioestrogenic agent in late breast cancer. Br J Cancer 25: 270–275, 1971

  18. 18.

    Boyd S: On oophorectomy in cancer of the breast. Br Med J 2: 1161–1167, 1900

  19. 19.

    Skipper HE, Schabel FM Jr: Quantitative and cytokinetic studies in experimental tumor models. In: Holland JF, Frei E III (eds) Cancer Medicine. Lea and Febiger, Philadelphia, PA, 1982, pp 663–685

  20. 20.

    Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51: 6493–6505, 1991

  21. 21.

    Retsky MW, Swartzendruber DE, Wardwell RH, Bame P: Is Gompertzian or exponential kinetics a valid description of human cancer growth? Med Hypotheses 33: 95–106, 1990

  22. 22.

    Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52: 2127–2137, 1992

  23. 23.

    DeVita VT Jr, Hubbard SM, Longo DL: The chemotherapy of lymphomas: looking back, moving forward - the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 47: 5810–5824, 1987

  24. 24.

    Stewart THM, Hollinshead AC, Raman S: Tumor dormancy: initiation maintenance and termination in animals and humans. Canad Soc Cardiovasc Thorac Surg 34: 321–325, 1991

  25. 25.

    Steel GG: Growth populations of tumors. Clarendon Press, Oxford, 1977

  26. 26.

    Fidler IJ: Cancer metastasis. Br Med J 47: 157–177, 1991

  27. 27.

    Ingleby H, Moore L: Periodic roentgenographic studies of a growing mammary cancer. Cancer 9: 749–752, 1956

  28. 28.

    Retsky MW, Wardwell RH, Speer JF: A computer simulation of breast cancer growth and treatment. Am Assoc Med Syst Info 3: 453–457, 1984

  29. 29.

    Speer JF, Petrosky VE, Retsky MW, Wardwell RH: A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44: 4124–4130, 1984

  30. 30.

    Retsky MW, Wardwell RH, Swartzendruber DE, Headley DL: Prospective computerized simulation of breast cancer: comparison of computer predictions with nine sets of biological and clinical data. Cancer Res 47: 4982–4987, 1987

  31. 31.

    Retsky M, Swartzendruber D, Wardwell R, Bame P, Petrosky V: Correspondence: re Larry Norton, A Gompertzian model of human breast cancer growth. Cancer Res 49: 6443–6444, 1989

  32. 32.

    Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442–447, 198

  33. 33.

    Shackney SE, McCormack GW, Cuchural GJ Jr: Growth rate patterns of solid tumors and their relation to responsiveness to therapy - an analytic review. Ann Int Med 89: 107–121, 1978

  34. 34.

    Retsky MW, Swartzendruber DE, Bame PD, Wardwell RW: A new paradigm for breast cancer. Proc. Fourth International Conference on Adjuvant Therapy of Breast Cancer, in Recent Results in Cancer Research, Springer Verlag, Heidelberg, 1993

  35. 35.

    Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G: Local recurrences following mastectomy: support for the concept of dormancy. J Natl Cancer Inst 86: 4545–4548, 1994

  36. 36.

    Lampi M, Veldhuis JD, Johnson ML: Saltation and stasis: a model of human growth. Science 258: 801–803, 1992

  37. 37.

    Curtsinger JW, Fukui HH, Townsend DR, Vaupel JW: Demography of genotypes: failure of the limited life-span paradigm in Drosophila melanogaster. Science 258: 461–463, 1992

  38. 38.

    Hayes DF: We may be lost, but we're sure makin' good time. Cancer Invest 11: 88–90, 1993

  39. 39.

    Goldhirsch A, Gelber RD, Castiglione M: Adjuvant therapy of breast cancer. Eur J Cancer 27: 389–399, 1991

  40. 40.

    Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10, 1983

  41. 41.

    Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71-85, 1992

  42. 42.

    Retsky MW, Swartzendruber DE, Wardwell RH, Bame PD: Predictions of effective treatment plans for very poor prognosis breast cancer patients using a computer model. Proc Am Assoc Cancer Res 30: 627, 1989

  43. 43.

    Beidler JL: Drug resistance: genotype versus phenotype -thirty-second GHA Clowes Memorial Award lecture. Cancer Res 54: 666–678, 1994

  44. 44.

    Muss HB, Case LD, Richards FR,et al.: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325: 1342–1348, 1991

  45. 45.

    Coates A, Gebski V, Bishop JF,et al.: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317: 1490–1495, 1987

  46. 46.

    Fisher B: The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 52: 2371–2383, 1992

Download references

Author information

Correspondence to Douglas E. Swartzendruber.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Swartzendruber, D.E., Retsky, M.W., Wardwell, R.H. et al. An alternative approach for treatment of breast cancer. Breast Cancer Res Tr 32, 319–325 (1994). https://doi.org/10.1007/BF00666009

Download citation

Key words

  • breast cancer
  • computer modeling
  • kinetics
  • therapy